Introduction {#s1}
============

Androgen receptor (*AR*) targeted therapy is highly effective in advanced prostate cancer but is complicated by the emergence of drug resistance, called castration-resistant prostate cancer (CRPC) ([@bib33]; [@bib41]). The most common mechanism of CRPC is restored *AR* signaling, primarily through amplification of *AR* ([@bib10]; [@bib29]). The importance of *AR* amplification as a clinically important drug resistance mechanism is underscored by recent data showing that *AR* amplification, detected in circulating tumor DNA or in circulating tumor cells (CTCs), is correlated with reduced clinical benefit from the next generation *AR* inhibitors abiraterone or enzalutamide ([@bib2]; [@bib25]).

Genomic landscape studies of prostate cancer have revealed several molecular subtypes defined by distinct genomic drivers ([@bib5]; [@bib8]; [@bib36]). In addition to this genomic heterogeneity, primary prostate cancers also display heterogeneity in *AR* transcriptional output, measured by an *AR* activity score ([@bib18]). Notably, these differences in transcriptional output occur in the absence of genomic alterations in *AR*, which are generally found only in CRPC ([@bib8]). One potential explanation for this heterogeneity in *AR* transcriptional output is through coactivators and other *AR* regulatory proteins such as *FOXA1*, *SPOP*, *FOXP1* and *TRIM24* ([@bib8]; [@bib16]; [@bib17]; [@bib26]; [@bib35]).

Much of the work to date has focused on inter-tumoral heterogeneity. Here, we address the topic of intra-tumoral heterogeneity in *AR* transcriptional output, for which we find substantial evidence in prostate cancer cell lines and in primary prostate tumors. Using a sensitive reporter of *AR* transcriptional activity to isolate cells with low versus high *AR* output, we show that high *AR* output cells have an enhanced response to low doses of androgen and reduced sensitivity to enzalutamide, in the absence of changes in *AR* mRNA and protein expression. To understand the molecular basis for these differences, we performed transcriptome and shRNA knockdown studies and identified three genes (*GREB1*, *KLF8* and *GHRHR*) upregulated in high *AR* output cells, all of which promote *AR* transcriptional activity through a feed-forward mechanism. Of these, we prioritized *GREB1* for further characterization because *GREB1* mRNA levels are increased in primary prostate tumors that have high *AR* activity. *GREB1* amplifies *AR* transcriptional activity through a two-part mechanism: by promoting *EP300* recruitment and by enhancing *AR* binding to chromatin. Importantly, *GREB1* knockdown converted high *AR* output cells to a low *AR* output state and restored enzalutamide sensitivity *in vivo*. Collectively, these data implicate *GREB1* as an *AR* signal amplifier that contributes to prostate cancer disease progression and antiandrogen resistance.

Results {#s2}
=======

Isolation of cells with low and high *AR* output but comparable *AR* expression {#s2-1}
-------------------------------------------------------------------------------

Previous work using a *KLK3* promoter/GFP reporter (PSAP-eGFP) showed that LNCaP prostate cancer cells display varying levels of eGFP expression. Characterization of low GFP cells in this analysis revealed reduced *AR* levels and increased expression of stem cell and developmental gene sets ([@bib27]). We explored this question in the context of the contemporary data on heterogeneity in *AR* transcriptional output using a different *AR*-responsive reporter, ARR~3~tk-eGFP, where eGFP expression is driven by the probasin promoter modified to contain three *AR *responsive elements ([@bib34]). LNCaP ([Figure 1](#fig1){ref-type="fig"}) and CWR22PC-EP ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) prostate cancer cells containing a single copy of the reporter construct were derived by infection with lentivirus containing the reporter at a low multiplicity of infection (MOI) ([Figure 1A](#fig1){ref-type="fig"}). Remarkably, we observed \>100 fold range in eGFP expression, as measured by flow cytometry, despite similar levels of *AR* by immunofluorescence microscopy ([Figure 1B,C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}).

![Characterization of prostate cancer cells with low vs. high *AR* output.\
(**A**) The LNCaP and CWR22Pc-EP reporter cell lines were generated by lentiviral infection with the eGFP *AR* reporter construct (details can be found in Materials and methods). Cells with stable integration of the construct were positively sorted by mCherry expression using flow cytometry. (**B**) LNCaP cells infected with the *AR* reporter display variable expression levels of eGFP (green) and AR (magenta). Nuclei were labeled with DAPI (blue). (**C**) LNCaP cells with low (ARsig-lo) or high (ARsig-hi) *AR* activities were sorted using flow cytometry based on eGFP *AR*-reporter expression. (**D--E**) LNCaP ARsig-hi cells have higher *AR* output while having the same level of *AR*. The q-PCR data (**D**) is presented as mean fold change ±SD relative to the bulk population. NS = not significant, \*\*\*\*p\<0.0001, one-way ANOVA compared to the bulk population. (**F**) Gene set enrichment analysis (GSEA) shows that the gene sets up- and down-regulated by androgen are enriched in LNCaP ARsig-hi and ARsig-lo cells, respectively. (**G**) LNCaP ARsig-lo and ARsig-hi cells maintain their *AR* activity levels over time. (**H**) LNCaP ARsig-hi cells showed enhanced upregulation of *AR* target genes in response to DHT treatment. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001, one-way ANOVA compared to the bulk population. (**I**) LNCaP/AR xenografts derived from ARsig-hi cells become resistant to enzalutamide faster than other populations. The bulk, sorted ARsig-lo and ARsig-hi cells were injected into physically castrated mice and the mice were treated with enzalutamide immediately after injection. Data is presented as mean ±SEM (N = 10). NS = not significant, \*p\<0.05, one-way ANOVA.\
10.7554/eLife.41913.008Figure 1---source data 1.GSEA Results (ARsig-lo vs. ARsig-hi).](elife-41913-fig1){#fig1}

We then used flow cytometry to isolate eGFP-positive cells from both ends of the spectrum of *AR* transcriptional output, which we refer to as ARsig-hi (high *AR* output) and ARsig-lo (low *AR* output) cells, respectively ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). ARsig-hi cells also express higher levels of endogenous *AR* target genes (*FKBP5*, *KLK3*, *TRPM8*) ([Figure 1D,E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}), and have an overall increase in *AR* transcriptional activity based on RNA-sequencing analysis ([Figure 1F](#fig1){ref-type="fig"}). In addition, the ARsig-lo and ARsig-hi transcriptional phenotypes remain stable for over 30 days post-sorting ([Figure 1G](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). Interestingly, ARsig-lo cells showed upregulation of gene sets related to proliferation and cell cycle ([Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). Of note, [@bib27] reported downregulation of these gene sets in their low/absent *KLK3* cells, suggesting that the two reporters read out different transcriptional activities. Importantly, the difference in *AR* output between ARsig-lo and ARsig-hi cells is not explained by different levels of *AR* expression or nuclear translocation, since both were comparable in each subpopulation ([Figure 1D,E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B,C](#fig1s1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).

We next asked if isolated ARsig-lo and ARsig-hi populations have different responses to ligands such as dihydrotestosterone (DHT) or antagonists such as enzalutamide. ARsig-hi cells showed enhanced sensitivity to DHT in a dose-dependent manner ([Figure 1H](#fig1){ref-type="fig"}; [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). This result is similar to the effect of increased *AR* expression in conferring sensitivity to low doses of androgen ([@bib10]), but now without a change in *AR* level. To address sensitivity to enzalutamide, we used LNCaP/AR xenografts (derived from LNCaP cells) because this model has a track record of revealing clinically relevant mechanisms of enzalutamide resistance ([@bib3]; [@bib4]). As we did with LNCaP and CWR22PC-EP cells, we derived ARsig-lo and ARsig-hi subpopulations by flow cytometry and also observed differential *AR* output despite similar levels of *AR* expression ([Figure 1---figure supplement 3A--C](#fig1s3){ref-type="fig"}). Remarkably, ARsig-hi cells developed enzalutamide resistance significantly faster that ARsig-lo or parental cells when injected into castrated mice treated with enzalutamide ([Figure 1I](#fig1){ref-type="fig"}).

Having demonstrated heterogeneous *AR* output within prostate cancer cell lines, we asked if similar, intra-tumoral heterogeneity is observed clinically by immunohistochemical analysis of *KLK3* and *AR* expression in several primary cancers. Consistent with previous reports ([@bib27]; [@bib31]), we observed heterogeneous *KLK3* staining that is not strictly correlated with *AR* level. For example, we found variable intensity of *KLK3* staining in tumor cells with comparable levels of *AR* staining (lined boxes; [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}) and, conversely, variable intensity of *AR* staining in tumor cells with similar *KLK3* staining (dotted circles; [Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Although this is a small dataset, the results indicate that the *AR* transcriptional heterogeneity we observe in prostate cancer cell lines is present in patient samples. Emerging technologies for conducting single cell RNA and protein analysis in clinical material will enable deeper investigation of this question.

GREB1 maintains high AR transcriptional output {#s2-2}
----------------------------------------------

To elucidate the molecular basis underlying the differences in ARsig-lo and ARsig-hi cells, we performed RNA-sequencing and found 69 genes upregulated in ARsig-lo cells and 191 genes upregulated in ARsig-hi cells (fold change ≥1.5, p\<0.05, [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). In addition to enrichment of gene sets regulated by androgen ([Figure 1F](#fig1){ref-type="fig"}), human prostate luminal and basal cell gene sets were enriched in ARsig-hi and ARsig-lo cells, respectively ([Figure 2A](#fig2){ref-type="fig"}). Based on these results, we postulated that high *AR* output could be a consequence of upregulation of transcriptional co-activators and/or of genes involved in luminal differentiation. We therefore filtered the list of 191 genes upregulated in ARsig-hi cells and identified 33 genes annotated as co-activators or luminal genes ([Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}), then measured the consequence of shRNA knockdown of each one on *AR* output in ARsig-hi cells ([Figure 2B](#fig2){ref-type="fig"}). Three of the 33 candidate genes (*GREB1*, *GHRHR*, *KLF8*) inhibited *AR* activity when knocked down in ARsig-hi cells, with successful knockdown confirmed by qRT-PCR ([Figure 2C,D](#fig2){ref-type="fig"}). *AR* knockdown served as a positive control, and *ACPP* (one of the 30 genes that did not score) served as a negative control. Interestingly, all three hits are transcriptional upregulated by DHT simulation ([Figure 2E](#fig2){ref-type="fig"}), which likely explains their increased expression in ARsig-hi cells.

![Knockdown of the three *AR* regulated genes, *GREB1*, *GHRHR* and *KLF8*, inhibited *AR* activity in cells with high *AR* activity.\
(**A**) Gene set enrichment analysis (GSEA) shows that genes upregulated in human prostate luminal and basal cells are enriched in LNCaP ARsig-hi and ARsig-lo cells, respectively. (**B**) The schematic of the knockdown study with 33 selected genes upregulated in LNCaP ARsig-hi cells. Details can be found in the Materials and methods. (**C**) The flow cytometry results show that the knockdown of *GREB1*, *GHRHR* and *KLF8* inhibited *AR* reporter activity in LNCaP ARsig-hi cells. Top: The flow cytometry plot of one of the duplicate assays is shown. Bottom: The normalized median fluorescence intensity (MFI) of eGFP reporter in each assay is shown. *AR* shRNA was used as a positive control. *ACPP* shRNA is shown as a representative hairpin that had no effect on reporter activity. (**D**) The knockdown level of *AR*, *GREB1*, *GHRHR*, *KLF8* and *ACPP* from the cells represented in (**C**). The q-PCR data is presented as mean fold change ±SD relative to the shRenilla control. (**E**) The transcription of *GREB1*, *GHRHR* and *KLF8* is regulated by androgen in LNCaP. The data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001, one-way ANOVA compared to the DMSO control. (**F**) The correlation between RNA levels of *GREB1*, *GHRHR* and *KLF8* and AR score in 333 TCGA primary prostate tumors were analyzed using Pearson's correlation analysis (**r**). The RNA levels of the three genes were also compared between tumors with lowest (ARsig-lo, red points) and highest (ARsig-hi, blue points) AR score (5% of 333 cases: 17 cases each). NS = not significant, \*\*p\<0.01, \*\*\*\*p\<0.0001, unpaired t-test. \*One data point (*GHRHR*, x = −0.67, y = 1252.6072) is outside the y-axis limit. (**G**) The *GREB1* function is inhibited by CRISPR/Cas9 in four LNCaP ARsig-hi sublines. (Top) *AR* reporter activity was inhibited in all four *GREB1* CRISPR cell lines compared to control (SgNT). (Bottom) An example of the genomic alteration in the targeted sequence for each cell line is shown. (**H**) The CRISPR/Cas9-mediated inhibition of *GREB1* suppressed KLK3 expression without affecting the AR level.\
10.7554/eLife.41913.011Figure 2---source data 1.Differentially expressed genes between ARsig-lo vs. ARsig-hi.\
10.7554/eLife.41913.012Figure 2---source data 2.Summary of Median eGFP Intensity of small-scale shRNA screen.\
10.7554/eLife.41913.013Figure 2---source data 3.AR scores and RNA levels of *GREB1*, *GHRHR* and *KLF8* of 333 TCGA cases.](elife-41913-fig2){#fig2}

Among the three, *GREB1* emerged as the most compelling candidate for further investigation based on interrogation of clinical datasets. Specifically, we found a statistically significant positive correlation (*r*) between *GREB1* RNA level and *AR* output score ([@bib8]; [@bib18]) across the primary prostate tumors from the TCGA dataset, but not *GHRHR* or *KLF8* ([Figure 2F](#fig2){ref-type="fig"}). Consistent with this, increased expression of *GREB1*, but not *GHRHR* or *KLF8*, was observed in TCGA cases with high *AR* scores (top 5%) versus low *AR* scores (bottom 5%) ([Figure 2F](#fig2){ref-type="fig"}, [Figure 2---source data 3](#fig2sdata3){ref-type="supplementary-material"}). To be sure that *GREB1* is relevant in other model systems, we confirmed *GREB1* upregulation in CWR22PC-EP ARsig-hi cells ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}) and reduced *AR* output after *GREB1* knockdown ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). We further validated the knockdown data using CRISPR/Cas9, which also showed inhibition of *AR* output (by flow cytometry) and highly reduced *KLK3* expression in LNCaP ARsig-hi sublines expressing different sgRNAs targeting *GREB1*, without detectable changes in *AR* protein level ([Figure 2G,H](#fig2){ref-type="fig"}).

GREB1 amplifies AR transcriptional activity by enhancing AR DNA binding {#s2-3}
-----------------------------------------------------------------------

*GREB1* was first reported as an estrogen-regulated gene in breast cancer ([@bib28]) then shown to bind directly to ER, presumably through its LxxLL motif, and function as an ER coactivator by promoting interaction with cofactors ([@bib23]). To determine if *GREB1* also functions as an *AR* coactivator, we introduced exogenous *GREB1* (HA-GREB1) into ARsig-lo LNCaP and CWR22PC-EP cells and derived stably expressing sublines ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). *GREB1* overexpression enhanced DHT-induced *AR* target gene expression in a dose-dependent manner ([Figure 3B,C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), indicating that *GREB1* also promotes *AR* activity.

![*GREB1* amplifies *AR* transcriptional activity by enhancing *AR* binding to chromatin.\
(**A**) *GREB1* overexpression in LNCaP ARsig-lo cells with stable integration of a *GREB1* lentiviral vector containing an amino-terminal HA-tag. (**B**) LNCaP ARsig-lo cells with *GREB1* overexpression show higher induction of *AR* target genes in response to DHT treatment. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. NS = not significant, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, \*\*\*\*p\<0.0001, unpaired t-test compared to the control cells. (**C**) *GREB1* overexpression in LNCaP ARsig-lo cells increases protein levels of *AR* target genes without affecting *AR* level. (**D**) Co-immunoprecipitation using nuclear extracts shows an interaction between AR and GREB1 (HA) in LNCaP ARsig-lo cells. (**E**) ChIP against the HA-tag shows *GREB1* binding on the *KLK3* and *FKBP5* enhancer regions in LNCaP ARsig-lo cells. \*p\<0.05, unpaired t-test. (**F--G**) LNCaP ARsig-hi cells have increased *EP300* binding on the *KLK3* and *FKBP5* enhancer regions in a *GREB1* dependent manner. \*p\<0.05, \*\*p\<0.01, unpaired t-test. (**H**) *GREB1* knockdown or CRISPR decreases *AR* binding to *KLK3* enhancer in LNCaP ARsig-hi cells. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, unpaired t-test (shRenilla vs. shGREB1), one-way ANOVA (SgNT vs. SgGREB1). The ChIP q-PCR data (**E--H**) is presented as mean percentage input ±SD. (**I**) Overlap of *AR* ChIP-sequencing peaks shows that *AR* peaks are disrupted by *GREB1* knockdown in LNCaP ARsig-hi cells. (**J**) ChIP-sequencing summary plot shows that *AR* enrichment across the *AR*-binding sites is reduced by *GREB1* knockdown. (**K**) Example of AR genomic peaks at *NKX3-1*.](elife-41913-fig3){#fig3}

In breast cancer, *GREB1* functions as a coactivator through binding to ER and recruitment of the EP300/CBP complex to ER target genes ([@bib23]). We find that *GREB1* functions similarly in prostate cells, as shown by co-immunoprecipitation documenting AR-GREB1 interaction ([Figure 3D](#fig3){ref-type="fig"}) and ChIP experiments showing recruitment of *GREB1* to *KLK3* and *FKBP5* enhancer regions ([Figure 3E](#fig3){ref-type="fig"}). Furthermore, ARsig-hi cells showed a *GREB1*-dependent increase in *EP300* binding ([Figure 3F,G](#fig3){ref-type="fig"}) and *GREB1* overexpression increased *EP300* recruitment to *AR* target genes in ARsig-lo cells ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}). Knockdown of *EP300* suppressed the effect of *GREB1* overexpression on DHT-induced *AR* target gene upregulation in ARsig-lo cells ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}, refer also to [Figure 3B](#fig3){ref-type="fig"}), suggesting that *EP300* is required for the function of *GREB1* as an *AR* co-factor.

In addition to this canonical coactivator function of promoting assembly of an active transcription complex, we found that *GREB1* also impacts *AR* DNA binding. For example, knockdown or CRISPR deletion of *GREB1* in ARsig-hi cells significantly reduced binding of *AR* to the *KLK3* enhancer and, conversely, *GREB1* overexpression promoted *AR* recruitment in ARsig-lo cells ([Figure 3H](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). *AR* ChIP-sequencing revealed that this effect is genome-wide, with a significant reduction in the mean height of *AR* peaks in *GREB1*-depleted cells ([Figure 3I--K](#fig3){ref-type="fig"}). Importantly, the location of *AR* peaks (enhancer, promoter) was identical in intact versus *GREB1* knockdown cells and there were no differences in consensus binding sites ([Figure 3---figure supplement 2D,E](#fig3s2){ref-type="fig"}). Therefore, *GREB1* enhances *AR* DNA efficiency but not alter DNA-binding site specificity. As seen previously in our analysis of ARsig-hi cells, total and nuclear *AR* levels were not changed by *GREB1* knockdown or overexpression ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 2F,G](#fig3s2){ref-type="fig"}).

Of note, earlier studies of *GREB1* in breast cancer did not report any effect on ER DNA binding ([@bib23]), which we confirmed by *GREB1* knockdown in MCF7 breast cancer cells ([Figure 3---figure supplement 3A,B](#fig3s3){ref-type="fig"}). Thus, *GREB1* functions as a coactivator of both ER and AR but through somewhat different mechanisms. To address the possibility that other hormone receptor coactivators might also function differently in prostate cells, we asked if *NCOA1* and *NCOA2*, previously shown to recruit the EP300/CBP complex to *AR* ([@bib21]), also influence *AR* DNA binding. To do so, we knocked down both genes in ARsig-hi cells based on prior work showing redundancy between *NCOA1* and *NCOA2* ([@bib21]; [@bib38]). *AR* reporter activity and target gene expression was inhibited in *NCOA1/2*-depleted cells, as expected, but *AR* occupancy of *AR* binding sites was unchanged ([Figure 3---figure supplement 3C--E](#fig3s3){ref-type="fig"}). Thus, in addition to a role in EP300/CBP recruitment, *GREB1* has unique effects on *AR* DNA binding that distinguish it from other coactivators.

GREB1 is required for enzalutamide resistance of high AR output cells {#s2-4}
---------------------------------------------------------------------

Having demonstrated that *GREB1* is overexpressed in ARsig-hi cells and functions as an *AR* coactivator, we asked if *GREB1* is required for maintenance of the ARsig-hi state. First we evaluated the consequences of *GREB1* knockdown on transcription. Consistent with experiments in ARsig-lo cells showing that *GREB1* overexpression enhanced *AR* transcriptional activity ([Figure 3B,C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), *GREB1* knockdown inhibited baseline and DHT-induced *AR* target gene expression in ARsig-hi cells ([Figure 4A--C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 1A,B](#fig4s1){ref-type="fig"}). RNA-sequencing confirmed enrichment of androgen down-regulated gene sets in *GREB1*-depleted cells ([Figure 4D](#fig4){ref-type="fig"}) as well as downregulation of the 20 *AR* target genes used to calculate the *AR* activity score in TCGA tumors ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}). *GREB1* knockdown cells also showed enrichment of the same prostate basal gene set that was enriched in ARsig-lo cells ([Figure 4D](#fig4){ref-type="fig"}, refer also to [Figure 2A](#fig2){ref-type="fig"}). Additional analysis of RNA-seq data suggests that *GREB1* is a major molecular determinant of the ARsig-hi state: specifically, (i) *GREB1* knockdown impaired the induction of \>70% of all DHT-induced genes ([Figure 4E](#fig4){ref-type="fig"}, [Figure 4---source datas 1](#fig4sdata1){ref-type="supplementary-material"} and [2](#fig4sdata2){ref-type="supplementary-material"}) and (ii) the top 100 gene sets enriched in *GREB1*-depleted ARsig-hi cells and ARsig-lo cells show significant overlap ([Figure 4F](#fig4){ref-type="fig"}, [Figure 4---source data 3](#fig4sdata3){ref-type="supplementary-material"}).

![*GREB1* is the major molecular determinant of ARsig-hi cells.\
(**A--B**) Knockdown of *GREB1* inhibited *AR* target gene expression in LNCaP ARsig-hi cells. The q-PCR data (**A**) is presented as mean fold change ±SD relative to the shRenilla control. \*\*p\<0.01, \*\*\*\*p\<0.0001, unpaired t-test. (**C**) Knockdown of *GREB1* suppressed the enhanced *AR* transcriptional activity in LNCaP ARsig-hi cells. The q-PCR data is presented as mean fold change ±SD relative to the DMSO control. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, unpaired t-test compared to the shRenilla control. (**D**) Gene set enrichment analysis (GSEA) shows that the gene sets up- and down-regulated by androgen are enriched in LNCaP ARsig-hi control and *GREB1* knockdown cells, respectively and genes upregulated in human prostate luminal and basal cells are enriched in ARsig-hi control and *GREB1* depleted cells, respectively. (**E**) Venn diagram showing that 70.5% of DHT-induced genes in control LNCaP ARsig-hi cells were inhibited by *GREB1* knockdown. (**F**) Venn diagram showing that 64% of the top 100 gene sets enriched in LNCaP ARsig-lo overlap with the top 100 gene sets enriched in *GREB1* depleted ARsig-hi cells. (**G**) Knockdown of *GREB1* inhibited development of enzlutamide-resistant LNCaP/AR xenografts derived from ARsig-hi cells. The sorted LNCaP/AR ARsig-hi cells were infected with control or three different shRNAs targeting *GREB1* and injected into physically castrated mice. Mice were treated with enzalutamide immediately after injection. Data is presented as mean ±SEM (N = 10). \*p\<0.05, \*\*p\<0.01, one-way ANOVA compared to the shRenilla control. (**H**) The SU2C cases that have received enzalutamide (Enz) have increased level of *GREB1* (unpaired *t*-test).\
10.7554/eLife.41913.020Figure 4---source data 1.Upregulated genes in ARsig-hi shRenilla DHT vs. veh.\
10.7554/eLife.41913.021Figure 4---source data 2.Upregulated genes in ARsig-hi shGREB1 DHT vs. veh.\
10.7554/eLife.41913.022Figure 4---source data 3.GSEA Results (ARsig-hi shRenilla DHT vs. shGREB1 DHT).](elife-41913-fig4){#fig4}

Earlier we showed that ARsig-hi cells rapidly acquire resistance to enzalutamide (refer to [Figure 1I](#fig1){ref-type="fig"}). To determine the role of *GREB1* in this drug resistant phenotype, we performed knockdown experiments using the LNCaP/AR xenograft. After confirming that *AR* activity was inhibited in ARsig-hi cells ([Figure 4---figure supplement 1D,E](#fig4s1){ref-type="fig"}), we injected LNCaP/AR ARsig-hi xenografts with *GREB1* shRNAs into castrated mice treated with enzalutamide and found a significant delay in the development of enzalutamide resistance after 10 weeks ([Figure 4G](#fig4){ref-type="fig"}). Clinical data from CRPC patients also supports for a role of *GREB1* in enzalutamide resistance. Although the samples are not matched pre- and post-treatment, we observed an overall increase in *GREB1* expression in those who progressed on enzalutamide treatment ([Figure 4H](#fig4){ref-type="fig"}). When we analyzed tumor purity content and stromal signature score as described previously ([@bib9]; [@bib32]; [@bib42]), no significant difference was observed between samples collected pre- vs. post-treatment ([Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}).

Discussion {#s3}
==========

There is abundant evidence from tumor sequencing studies that genomic alterations in *AR* (amplification and/or mutation) are present in over 50% of CRPC patients ([@bib8]; [@bib29]) and that *AR* amplification is associated with a less favorable clinical response to abiraterone or enzalutamide treatment ([@bib2]). Therefore, high levels of *AR* transcriptional output can promote castration-resistant disease progression. Here we show that prostate cancers can amplify *AR* output through increased expression of the dual AR/ER coactivator *GREB1*, in the absence of genomic *AR* alterations. As with genomic *AR* amplification, increased *AR* output driven by high *GREB1* expression is also associated with enzalutamide resistance.

In addition to demonstrating the importance of transcriptional heterogeneity in drug resistance, we also show that *GREB1* amplifies *AR* activity by a novel two-part mechanism. Similar to canonical coactivators such as *NCOA1/2*, *GREB1* binds *AR* and promotes the assembly of an active transcription complex by recruitment of histone acetyl transferases such as EP300/CBP ([@bib20]). However, *GREB1* has the additional property of improving the efficiency of *AR* binding to DNA, which further enhances *AR* transcriptional output. Although conceptually distinct from canonical coactivators, this dual mechanism of *AR* activation is may not be unique to *GREB1*. For example, *TRIM24* has been shown to function as an oncogenic *AR* cofactor and, similar to *GREB1*, knockdown of *TRIM24* impairs recruitment of *AR* to target genes ([@bib17]). Curiously, the effect of *GREB1* on *AR* DNA binding is not seen with ER, suggesting different conformational consequences of *GREB1* binding on AR and ER, respectively, then influence DNA binding.

One curious observation is the fact that prostate cancers can maintain transcriptional heterogeneity as a stable phenotype, despite the fact that *GREB1* expression drives a feed forward loop which, in principle, should result in an increased fraction of high *AR* output cells over time. One potential explanation for the ability of these populations to maintain stable proportions of high versus low *AR* output cells at steady state is the fact that androgen has growth inhibitory effects at higher concentrations ([@bib12]). Because *GREB1* amplifies the magnitude of *AR* output in response to normal (growth stimulatory) androgen concentrations, the biologic consequence of high *GREB1* levels could be the same growth suppression seen with high androgen concentrations. This model predicts that high *AR* output cells would gain a fitness advantage under conditions of androgen deprivation or pharmacologic *AR* inhibition, as demonstrated by the enzalutamide resistance observed in xenograft models.

Further work is required to understand the clinical implications of our work, particularly whether *GREB1* levels in CRPC patients are predictive of response to next generation *AR* therapy. While we show that *GREB1* levels are elevated in the tumors of CRPC patients who have progressed on enzalutamide, it will be important to address this question prospectively, prior to next generation *AR* therapy. It is also important to note that the positive correlation of *GREB1* levels with high *AR* activity is largely based on the hormone-naïve TCGA cohort. It is also possible that the LNCaP cell line used for functional studies has an *AR* point mutation could potentially influence response to *GREB1* expression, but we obtained similar results in 22PC cells that lack this mutation ([@bib37]). In terms of therapeutic implications, *GREB1* knockdown experiments provide genetic evidence that *GREB1* is required for in vivo enzalutamide resistance in xenograft models. Although pharmacologic strategies to inhibit *GREB1* function are not currently available, a small molecule inhibitor that blocks protein-protein interactions between the AR N-terminal domain and CBP/EP300 is currently in clinical development ([@bib1]) (NCT02606123). This work provides precedent that similar strategies to disrupt GREB1/AR interaction may be possible.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\    Designation              Source or\                                                                                                                                                    Identifiers                                                      Additional\
  (species) or\                             reference                                                                                                                                                                                                                      information
  resource                                                                                                                                                                                                                                                                 
  ---------------- ------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- -------------------------------------------------------------------
  Cell line\       LNCaP                    ATCC                                                                                                                                                          CRL-1740,\                                                       
  (*H. sapiens*)                                                                                                                                                                                          RRID:[CVCL_1379](https://scicrunch.org/resolver/CVCL_1379)       

  Cell line\       LNCaP/AR                 PMID: 14702632                                                                                                                                                                                                                 
  (*H. sapiens*)                                                                                                                                                                                                                                                           

  Cell line\       CWR22Pc-EP               PMID: 28059768                                                                                                                                                                                                                 
  (*H. sapiens*)                                                                                                                                                                                                                                                           

  Antibody         AR                       abcam                                                                                                                                                         ab108341,\                                                       WB (1:1000),\
                                                                                                                                                                                                          RRID:[AB_10865716](https://scicrunch.org/resolver/AB_10865716)   IP (5 ug/IP)

  Antibody         AR                       Santa Cruz                                                                                                                                                    sc-816,\                                                         IF (1:500),\
                                                                                                                                                                                                          RRID:[AB_1563391](https://scicrunch.org/resolver/AB_1563391)     ChIP (5 ug/IP)

  Antibody         AR                       Agilent                                                                                                                                                       441                                                              IHC

  Antibody         KLK3                     Cell Signaling\                                                                                                                                               5365                                                             WB (1:500)
                                            Technology                                                                                                                                                                                                                     

  Antibody         KLK3                     Biogenex                                                                                                                                                                                                                       IHC

  Antibody         FKBP5                    Cell Signaling\                                                                                                                                               8245,\                                                           WB (1:500)
                                            Technology                                                                                                                                                    RRID:[AB_10831198](https://scicrunch.org/resolver/AB_10831198)   

  Antibody         TRPM8                    Epitomics                                                                                                                                                     3466--1,\                                                        WB (1:1000)
                                                                                                                                                                                                          RRID:[AB_10715643](https://scicrunch.org/resolver/AB_10715643)   

  Antibody         tubulin                  Santa Cruz                                                                                                                                                    sc-9104,\                                                        WB (1:1000)
                                                                                                                                                                                                          RRID:[AB_2241191](https://scicrunch.org/resolver/AB_2241191)     

  Antibody         Cyclophilin B            abcam                                                                                                                                                         ab178397                                                         WB (1:100,000)

  Antibody         BRD4                     Cell Signaling\                                                                                                                                               13440,\                                                          WB (1:1000)
                                            Technology                                                                                                                                                    RRID:[AB_2687578](https://scicrunch.org/resolver/AB_2687578)     

  Antibody         TOP2B                    abcam                                                                                                                                                         ab58442,\                                                        WB (1:1000)
                                                                                                                                                                                                          RRID:[AB_883147](https://scicrunch.org/resolver/AB_883147)       

  Antibody         HA                       Cell Signaling                                                                                                                                                3724,\                                                           WB (1:1000)
                                                                                                                                                                                                          RRID:[AB_1549585](https://scicrunch.org/resolver/AB_1549585)     

  Antibody         HA                       Abcam                                                                                                                                                         ab9110,\                                                         ChIP (5 ug/IP)
                                                                                                                                                                                                          RRID:[AB_307019](https://scicrunch.org/resolver/AB_307019)       

  Antibody         Alexa Fluor 647          Invitrogen/\                                                                                                                                                  A-31573,\                                                        IF (1:1000)
                                            Thermo Fisher                                                                                                                                                 RRID:[AB_2536183](https://scicrunch.org/resolver/AB_2536183)     

  Antibody         p300                     Santa Cruz                                                                                                                                                    sc-585,\                                                         ChIP (5 ug/IP)
                                                                                                                                                                                                          RRID:[AB_2231120](https://scicrunch.org/resolver/AB_2231120)     

  Antibody         ER                       Santa Cruz                                                                                                                                                    sc-8002,\                                                        ChIP (5 ug/IP)
                                                                                                                                                                                                          RRID:[AB_627558](https://scicrunch.org/resolver/AB_627558)       

  Antibody         normal rabbit IgG        Millipore Sigma                                                                                                                                               12--370,\                                                        ChIP (5 ug/IP)
                                                                                                                                                                                                          RRID:[AB_145841](https://scicrunch.org/resolver/AB_145841)       

  Antibody         Protein A/G\             Santa Cruz                                                                                                                                                    sc-2003,\                                                        
                   agarose beads                                                                                                                                                                          RRID:[AB_10201400](https://scicrunch.org/resolver/AB_10201400)   

  Recombinant\     ARR3tk-eGFP/\            This paper                                                                                                                                                                                                                     Addgene plasmid\
  DNA reagent      SV40-mCherry                                                                                                                                                                                                                                            \#24304

  Recombinant\     SCEP-shRenilla           This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shAR.177            This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shGREB1-1           This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shGREB1-2           This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shGREB1-3           This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shKLF8.3467         This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shKLF8.2180         This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shKLF8.2684         This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shGHRHR.544         This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shGHRHR.1571        This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shGHRHR.1583        This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-sh-p300-1           This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-sh-p300-2           This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shSRC1-1            This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shSRC2-1            This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     SCEP-shSRC2-2            This paper,\                                                                                                                                                                                                                   
  DNA reagent                               PMID: 24332856                                                                                                                                                                                                                 

  Recombinant\     lentiCRISPRv2-SgNT       PMID: 24336569                                                                                                                                                                                                                 Addgene\
  DNA reagent                                                                                                                                                                                                                                                              plasmid \#52961

  Recombinant\     lentiCRISPRv2-\          This paper                                                                                                                                                                                                                     Addgene\
  DNA reagent      SgGREB1-7                                                                                                                                                                                                                                               plasmid \#52961

  Recombinant\     lentiCRISPRv2-\          This paper                                                                                                                                                                                                                     Addgene\
  DNA reagent      SgGREB1-8                                                                                                                                                                                                                                               plasmid \#52961

  Recombinant\     pCMV6-GREB1              PMID: 23403292                                                                                                                                                                                                                 
  DNA reagent                                                                                                                                                                                                                                                              

  Recombinant\     pLVX-TRE3G-\             This paper                                                                                                                                                                                                                     
  DNA reagent      HA-GREB1                                                                                                                                                                                                                                                

  Sequence-\       q-PCR primers            This paper                                                                                                                                                                                                                     See\
  based reagent                                                                                                                                                                                                                                                            [Supplementary file 1](#supp1){ref-type="supplementary-material"}

  Sequence-\       shRNAs                   This paper                                                                                                                                                                                                                     
  based reagent                                                                                                                                                                                                                                                            

  Sequence-\       gRNAs                    This paper                                                                                                                                                                                                                     
  based reagent                                                                                                                                                                                                                                                            

  Commercial\      QIAshredder              Qiagen                                                                                                                                                        79656                                                            
  assay or kit                                                                                                                                                                                                                                                             

  Commercial\      RNeasy Mini Kit          Qiagen                                                                                                                                                        74106                                                            
  assay or kit                                                                                                                                                                                                                                                             

  Commercial\      High Capacity\           thermo fisher                                                                                                                                                 4368814                                                          
  assay or kit     cDNA Reverse\                                                                                                                                                                                                                                           
                   Transcription Kit                                                                                                                                                                                                                                       

  Commercial\      QuantiFast SYBR\         Qiagen                                                                                                                                                        204057                                                           
  assay or kit     Green PCR Kit                                                                                                                                                                                                                                           

  Commercial\      BCA Protein Assay        ThermoFisher                                                                                                                                                  23225                                                            
  assay or kit                                                                                                                                                                                                                                                             

  Commercial\      Subcellular Protein\     ThermoFisher                                                                                                                                                  78840                                                            
  assay or kit     Fractionation Kit                                                                                                                                                                                                                                       

  Commercial\      Peira TM900 system       Peira bvba                                                                                                                                                                                                                     
  assay or kit                                                                                                                                                                                                                                                             

  Commercial\      the KAPA Biosystems\     Kapa Biosystems                                                                                                                                               KK8504                                                           
  assay or kit     Hyper Library\                                                                                                                                                                                                                                          
                   Prep Kit                                                                                                                                                                                                                                                

  Chemical\        FBS                      Omega Scientific                                                                                                                                              FB-11                                                            
  compound, drug                                                                                                                                                                                                                                                           

  Chemical\        Accumax                  Innovative Cell\                                                                                                                                              AM105                                                            
  compound, drug                            Technologies                                                                                                                                                                                                                   

  Chemical\        matrigel                 Corning                                                                                                                                                       356237                                                           
  compound, drug                                                                                                                                                                                                                                                           

  Chemical\        Laemmli sample\          BioRad                                                                                                                                                        1610747                                                          
  compound, drug   buffer                                                                                                                                                                                                                                                  

  Chemical\        4% formaldehyde          electron microscopy\                                                                                                                                          15714 s                                                          
  compound, drug                            sciences                                                                                                                                                                                                                       

  Chemical\        normal goat serum        Vector Lab                                                                                                                                                    S-1000,\                                                         
  compound, drug                                                                                                                                                                                          RRID:[AB_2336615](https://scicrunch.org/resolver/AB_2336615)     

  Chemical\        normal horse serum       Vector Lab                                                                                                                                                    S-2000,\                                                         
  compound, drug                                                                                                                                                                                          RRID:[AB_2336617](https://scicrunch.org/resolver/AB_2336617)     

  Chemical\        10% Triton X-\           Teknova                                                                                                                                                       T1105                                                            
  compound, drug   100 solution                                                                                                                                                                                                                                            

  Chemical\        DAPI mounting\           Vector Lab                                                                                                                                                    H-1200,\                                                         
  compound, drug   solution                                                                                                                                                                               RRID:[AB_2336790](https://scicrunch.org/resolver/AB_2336790)     

  Chemical\        charcoal-stripped\       Omega Scientific                                                                                                                                              FB-04                                                            
  compound, drug   dextran-treated fetal\                                                                                                                                                                                                                                  
                   bovine serum                                                                                                                                                                                                                                            

  Chemical\        Puromycin                Invivogen                                                                                                                                                     ant-pr                                                           
  compound, drug                                                                                                                                                                                                                                                           

  Chemical\        RPMI                     Media Preparation\                                                                                                                                                                                                             
  compound, drug                            Core at Sloan\                                                                                                                                                                                                                 
                                            Kettering Institute                                                                                                                                                                                                            

  Chemical\        DMEM                     Media Preparation\                                                                                                                                                                                                             
  compound, drug                            Core at Sloan\                                                                                                                                                                                                                 
                                            Kettering Institute                                                                                                                                                                                                            

  Software,\       Partek Genomics\         Partek Inc                                                                                                                                                    RRID:[SCR_011860](https://scicrunch.org/resolver/SCR_011860)     
  algorithm        Suite software                                                                                                                                                                                                                                          

  Software,\       FlowJo software          FlowJo software                                                                                                                                               RRID:[SCR_008520](https://scicrunch.org/resolver/SCR_008520)     version 9.9.6
  algorithm                                                                                                                                                                                                                                                                

  Software,\       GSEA                     Broad Institute                                                                                                                                               RRID:[SCR_003199](https://scicrunch.org/resolver/SCR_003199)     <http://www.broadinstitute.org/gsea/index.jsp>
  algorithm                                                                                                                                                                                                                                                                

  Software,\       GraphPad Prism           GraphPad Prism                                                                                                                                                RRID:[SCR_002798](https://scicrunch.org/resolver/SCR_002798)     version 7
  algorithm                                                                                                                                                                                                                                                                

  Software,\       STAR aligner             PMID: 23104886                                                                                                                                                RRID:[SCR_015899](https://scicrunch.org/resolver/SCR_015899)     
  algorithm                                                                                                                                                                                                                                                                

  Software,\       Kalisto                  PMID: 27043002                                                                                                                                                                                                                 
  algorithm                                                                                                                                                                                                                                                                

  Software,\       RSeQC                    PMID: 22743226                                                                                                                                                RRID:[SCR_005275](https://scicrunch.org/resolver/SCR_005275)     <http://broadinstitute.github.io/picard/>
  algorithm                                                                                                                                                                                                                                                                

  Software,\       DESeq2 package           <http://www-huber.embl.de/users/anders/DESeq>                                                                                                                 RRID:[SCR_015687](https://scicrunch.org/resolver/SCR_015687)     
  algorithm                                                                                                                                                                                                                                                                

  Software,\       Picard                   [http://broadinstitute.github.io/pica](http://broadinstitute.github.io/picard/index.html)[rd/index.html](http://broadinstitute.github.io/picard/index.html)   RRID:[SCR_006525](https://scicrunch.org/resolver/SCR_006525)     
  algorithm                                                                                                                                                                                                                                                                

  Software,\       MACS2                    PMID: 22936215                                                                                                                                                                                                                 
  algorithm                                                                                                                                                                                                                                                                

  Software,\       ChAsE                    PMID: 27378294                                                                                                                                                                                                                 
   algorithm                                                                                                                                                                                                                                                               

  Software,\       MEME-ChIP                PMID: 21486936                                                                                                                                                                                                                 
  algorithm                                                                                                                                                                                                                                                                

  Software,\       HOMER                    <http://homer.ucsd.edu/homer/>                                                                                                                                RRID:[SCR_010881](https://scicrunch.org/resolver/SCR_010881)     
  algorithm                                                                                                                                                                                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell lines {#s4-1}
----------

LNCaP and MCF7 cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in RPMI (LNCaP) or DMEM (MCF7) +10% FBS (Omega Scientific, Tarzana, CA). LNCaP/AR cell line was generated and maintained as previously described ([@bib10]). CWR22Pc was a gift from Marja T. Nevalainen (Thomas Jefferson University, Philadelphia, PA) and CWR22Pc-EP was generated and maintained as previously described ([@bib24]). Cell lines were authenticated by exome sequencing methods, and were negative for mycoplasma contamination testing.

Flow cytometry analysis and FACS-sorting {#s4-2}
----------------------------------------

Rapidly cycling eGFP *AR* reporter cells were collected using Accumax dissociation solution (Innovative Cell Technologies, San Diego, CA), and dead cells were counterstained with DAPI (Invitrogen, Grand Island, NY). For FACS-sorting of ARsig-lo and ARsig-hi cells, 5% of the entire population with lowest and highest eGFP expression was sorted out using BD FACSAria cell sorter. The 5% cutoff was used because it generates at least a 100-fold difference in median AR-GFP reporter signal between ARsig-lo and ARsig-hi cells and also allows us to have sufficient numbers of sorted cells to conduct various assays. For flow cytometric analysis of reporter activity, eGFP expression was measured using the BD-LDRII flow cytometer and analysis was done using FlowJo software.

Plasmid construction and cell transduction {#s4-3}
------------------------------------------

The lentiviral eGFP *AR* reporter (ARR~3~tk-eGFP/SV40-mCherry) was generated by switching 7xTcf promoter of 7xTcf-eGFP/SV40-mCherry (Addgene, Cambridge, MA, 24304) with probasin promoter containing 3xARE (ARR~3~tk) ([@bib34]). For shRNA knockdown experiments, SCEP vector was generated by substituting GFP cassette of SGEP (pRRL-GFP-miRE- PGK-PuroR, gift from Johannes Zuber) ([@bib14]) with mCherry cassette. The following guide sequences were used for knockdown:

shAR.177: TAGTGCAATCATTTCTGCTGGC

shGREB1-1: TTGTCAGGAACAGACACTGGTT

shGREB1-2: TTTCAGATTTATATGATTGGAG

shGREB1-3: TTGACAAGATACCTAAAGCCGA

shKLF8.3467: TTGAGTTCTAAAGTTTTCCTGA

shKLF8.2180: TATTTGTCCAAATTTAACCTAA

shKLF8.2684: TTATAAAACAATCTGATTGGGC

shGHRHR.544: TAAAAGTGGTGAACAGCTGGGT

shGHRHR.1571: TTTATTGGCTCCTCTGAGCCTT

shGHRHR.1583: TTCATTTACAGGTTTATTGGCT

shEP300-1: TCCAGAAAGAACTAGAAGAAAA

shEP300-2: TTAATCTATCTTCAGTAGCTTG

shNCOA1-1: TTCTTCTTGGAACTTGTCGTTT

shNCOA2-1: TTGCTGAACTTGCTGTTGCTGA

shNCOA2-2: TTAACTTTGCTCTTCTCCTTGC

shRenilla was previously described as Ren.713 targeting Renilla luciferase ([@bib14]). Pools of 3 shRNAs were used to knockdown *GREB1*, *KLF8* and *GHRHR* in a small-scale shRNA screen, and shGREB1-1 was used for further studies. For CRISPR/Cas9 experiments, lentiCRISPRv2 vector gifted by F. Zhang (Addgene, 52961) was used with the following guide sequences designed using <http://crispr.mit.edu/> website:

SgGREB1-7: AGGCATGTCCTGCGTGCCGC

SgGREB1-8: TCACGGGCATACGAGCAGTA sgNT was previously described ([@bib40]). pCMV6-GREB1 plasmid was a gift from J. Carroll (Cancer Research UK Cambridge Institute, Cambridge, UK). The lentiviral *GREB1* cDNA plasmid was constructed by cloning *GREB1* cDNA from pCMV6-GREB1 into Tet-inducible pLV-based lentiviral expression vector with HA-tag.

Lentiviral transduction of cells was performed as described previously ([@bib24]). To make *AR* reporter cell line, cells were infected with ARR~3~tk-eGFP/SV40-mCherry at low multiplicity of infection (MOI) to enable each cell has one copy of reporter construct, and the transduced cells were sorted by mCherry flow cytometry. To inactivate *GREB1* gene, we single-cell cloned the cells infected with lentiCRISPRv2 vector containing SgGREB1-7 or SgGREB1-8, and isolated a clone that had genomic alteration at target sequence. Three clones were generated by using SgGREB1-7 (SgGREB1-7-2, 7--11 and 7--12) and one clone was generated by using SgGREB1-8 (SgGREB1-8-2).

shRNA screen {#s4-4}
------------

FACS-based small-scale shRNA screen with 33 selected genes was performed as follows: FACS-sorted ARsig-hi cells were plated in 12 well plate (1.5 × 10^5^ cells per well, Corning, 353043) and each well was infected with pool of 3 SEPC shRNAs against each gene on the following day. Cells with stable integration of hairpins were selected with 2 μg/ml puromycin. 9 days after infection, half of the cells in each well was used to analyze eGFP *AR* reporter activity using flow cytometry, and the other half was subjected to qRT-PCR to determine knockdown level of the gene. We performed the screen in duplicate and each replicate included wells infected with shRenilla or shAR as controls. The median fluorescence intensity (MFI) of eGFP was measured using FlowJo software. The shRNAs decreased eGFP MFI more than 1.5 fold compared to shRenilla (normalized value lower than 0.667) in both duplicate were considered as hits. The list of 33 genes used in the screen and the summary of median eGFP intensity can be found at [Figure 2---source data 2](#fig2sdata2){ref-type="supplementary-material"}.

Xenograft assay {#s4-5}
---------------

To compare time to acquire enzalutamide resistance in vivo, FACS-sorted bulk, ARsig-lo and ARsig-hi populations derived from LNCaP/AR were cultured for 6 days after sorting to obtain enough number of cells for xenograft assay. 2 × 10^6^ cells were injected subcutaneously into the flank of physically castrated CB17 SCID mice in a 50:50 mix of matrigel (BD Biosciences, San Jose, CA) and regular culture medium (five mice, 10 tumors per group), and enzalutamide treatment was initiated on the day of injection. To test the effect of GREB1 knockdown on development of enzalutamide resistance, FACS-sorted ARsig-hi population derived from LNCaP/AR was infected with control or three different shGREB1 constructs 2 days after sorting. Cells with stable integration of hairpin were selected with 2 μg/ml puromycin. 5 days after infection, 2 × 10^6^ cells were injected subcutaneously into the flank of castrated CB17 SCID mice (five mice, 10 tumors per group), and enzalutamide treatment was initiated on the day of injection. The same cell populations used for injection were also used to test eGFP *AR* reporter activity using flow cytometry, and qRT-PCR to test knockdown level of *GREB1*. Measurements were obtained weekly using Peira TM900 system (Peira bvba, Belgium). All animal experiments were performed in compliance with the approved institutional animal care and use committee (IACUC) protocols (\#06-07-012) of the Research Animal Resource Center of Memorial Sloan Kettering Cancer Center.

Immunoblot, immunoprecipitation and immunostaining {#s4-6}
--------------------------------------------------

Protein was extracted from cells using Triton lysis buffer and quantified by BCA Protein Assay (ThermoFisher Scientific, Waltham, MA, 23225). Nuclear/cytoplasmic fractionation was achieved with Subcellular Protein Fractionation Kit (ThermoFisher Scientific, 78840). Protein lysates were subjected to SDS-PAGE and immunoblotted with the following antibodies against: AR (Abcam, Cambridge, United Kingdom, ab108341), KLK3 (Cell Signaling Technology, Danvers, MA, 5365), FKBP5 (Cell Signaling, 8245) TRPM8 (Epitomics, Burlingame, CA, 3466--1), tubulin (Santa Cruz Biotechnology, Dallas, TX, sc-9104), Cyclophilin B (Abcam, ab178397), BRD4 (Cell Signaling, 13440), TOP2B (Abcam, ab58442), HA (Cell Signaling, 3724).

For AR immunoprecipitation, at least 1.5 mg of total protein was incubated with AR antibody (Abcam, ab108341) overnight at 4°C followed by the addition of Protein A/G agarose beads (Santa Cruz, sc-2003) for 2 hr. Immune complexes were extensively washed with Triton buffer and solubilized using Laemmli sample buffer (BioRad, Hercules, CA).

For immunofluorescence staining, cells were fixed with 4% formaldehyde, permeabilized with 0.2% Triton-X, blocked with 5% normal goat and 5% normal horse serum, stained with anti-AR (Santa Cruz, sc-816) primary and Alexa Fluor 647 (Invitrogen) secondary antibodies, and mounted with DAPI mounting solution (Vector Lab, Burlingame, CA). For Immunohistochemistry, tumor sections were stained with anti-AR (Agilent, Santa Clara, CA, 441) and KLK3 (Biogenex, Fremont, CA) antibodies using Leica Bond RX (Leica Biosystems, Wetzlar, Germany).

Transcription analysis {#s4-7}
----------------------

Total RNA was isolated using the QiaShredder kit (Qiagen, Germantown, MD) for cell lysis and the RNeasy kit (Qiagen) for RNA purification. For quantitative PCR with reverse transcription (RT--qPCR), we used the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Grand Island, NY) to synthesize cDNA according to the manufacturer\'s protocol. Real-time PCR was performed using gene-specific primers and 2X SYBR green quantfast PCR Mix (Qiagen, 1044154). Data were analyzed by the DDCT method using GAPDH as a control gene and normalized to control samples, which were arbitrarily set to 1. To test DHT-induced *AR* target gene upregulation, cells were hormone-deprived in 10% charcoal-stripped dextran-treated fetal bovine serum (Omega Scientific) media for 2 days and then treated with indicated concentration of DHT for 24 hr. Triplicate measurements were made on at least three biological replicates. The primer sequences used for q-PCR are listed at [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

For RNA-seq, library preparation, sequencing and expression analysis were performed by the New York Genome Center. Libraries were prepared using TruSeq Stranded mRNA Library Preparation Kit in accordance with the manufacturer's instructions and sequenced on an Illumina HiSeq2500 sequencer (rapid run v2 chemistry) with 50 base pair (bp) reads. Partek Genomics Suite software (Partek Inc, St. Louis, MO) was used to analyze differentially expressed genes between ARsig-lo vs. ARsig-hi (Fold change ≥1.5, p\<0.05). To analyze RNA-seq data from ARsig-hi cells with shRenilla vs. shGREB1, reads were aligned to the NCBI GRCh37 human reference using STAR aligner ([@bib13]). Quantification of genes annotated in Gencode vM2 were performed using featureCounts and quantification of transcripts using Kalisto ([@bib7]). QC were collected with Picard and RSeQC ([@bib39]) (<http://broadinstitute.github.io/picard/>). Normalization of feature counts was done using the DESeq2 package (<http://www-huber.embl.de/users/anders/DESeq/>). Differentially expressed genes were defined as a 1.5 fold difference, p\<0.05 of DESeq-normalized expression. For GSEA, statistical analysis was performed with publicly available software from the Broad Institute (<http://www.broadinstitute.org/gsea/index.jsp>). The basal and luminal gene signatures used for GSEA ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) were generated by conducting RNA-sequencing with normal human basal vs. luminal prostate cells isolated as previously described ([@bib19]). Full description of this study will be reported separately.

ChIP {#s4-8}
----

ChIP experiments were performed as previously described ([@bib3]), using SDS-based buffers. Antibodies were used at a concentration of 5 ug per 1 mL of IP buffer, which encompassed approximately 8 million cells per IP. Antibodies used were: AR (Santa Cruz, sc-816), EP300 (Santa Cruz, sc-585), HA (Abcam, ab9110), ER (Santa Cruz, sc-8002). The primer sequences used for ChIP-qPCR are listed at [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

For ChIP--seq, library preparation and RNA-seq were performed by the NYU Genome Technology Center. Libraries were made using the KAPA Biosystems Hyper Library Prep Kit (Kapa Biosystems, Woburn, MA, KK8504), using 10 ng of DNA as input and 10 PCR cycles for library amplification. The libraries were sequenced on a HiSeq 2500, as rapid run v2 chemistry, paired-end mode of 51 bp read length.

The ChIP-seq reads were aligned to the human genome (hg19, build 37) using the program BWA (VN: 0.7.12; default parameters) within the PEMapper. Duplicated reads were marked by the software Picard (VN: 1.124; <http://broadinstitute.github.io/picard/index.html>) and removed. The software MACS2 ([@bib15]) (-q 0.1) was used for peak identification with data from ChIP input DNAs as controls. Peaks of sizes \> 100 bp and with at least one base pair covered by \>18 reads were selected as the final high confident peaks. Peaks from shGREB1/control conditions were all merged to obtain non-overlapping genomic regions, which were then used to determine conditional specific *AR* binding. Overlapped peaks were defined as those sharing at least one base pair. To generate graphs depicting *AR* ChIP--seq read density in ±2 kilobase regions of the *AR* peak summits, the same number of ChIP--seq reads from different conditions were loaded into the software ChAsE ([@bib43]), and the resulting read density matrices were sorted by the read densities in the shRenilla control, before coloring. The read density was also used to select peaks with significant signal difference between shGREB1 and controls. The criteria for assigning peaks to genes have been described previously ([@bib30]). The MEME-ChIP software ([@bib22]) was applied to 300 bp sequences around the peak summits for motif discovery, and the comparison of sequence motifs was also analyzed with HOMER (<http://homer.ucsd.edu/homer/>).

Analysis of human prostate cancer datasets {#s4-9}
------------------------------------------

All analysis of human prostate cancer data was conducted using previously published datasets of The Cancer Genome Atlas (TCGA) ([@bib8]) and PCF/SU2C ([@bib29]), which can be explored in the cBioPortal for Cancer Genomics (<http://www.cbioportal.org>). Tumor purity content was estimated computationally using the ABSOLUTE method ([@bib9]), based on mutant allele variant fractions and zygosity shifts. Stromal signature score was applied to the normalized RNA-seq expression dataset ([@bib42]).

Statistics {#s4-10}
----------

For comparison of pooled data between two different groups, unpaired t tests were used to determine significance. For comparison of data among three groups, one-way ANOVA was used to determine significance. In vitro assays represent three independent experiments from biological replicates, unless otherwise indicated. In all figures, \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 and \*\*\*\*p\<0.0001. For GSEA, statistical analysis was performed with publicly available software from the Broad Institute (<http://www.broadinstitute.org/gsea/index.jsp>). The sample size estimate was based on our experience with previous experiments ([@bib4]; [@bib6]; [@bib11]). No formal randomization process was used to assign mice to a given xenograft assay, and experimenters were not blinded.
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Decision letter

Tannock

Ian

Reviewing Editor

Princess Margaret Cancer Centre

Canada

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"*GREB1* amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Gert Attard (Reviewer \#2); Myles Brown (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The finding that *GREB1* amplifies androgen output in prostate cancer cell lines and does so by 2 mechanisms including enhancing AR binding and co-activator activity has implications for resistance of PC to enzalutamide and other AR targeting agents.

Essential revisions:

1\) Statistical tests/results should be added to the figure panels and should be more clearly specified throughout the text and in the figures.

2\) The authors use both LNCAP and LNCaP with stably over-expressing AR (for xenograft work and based on previous studies). The use of these models needs to be clarified in the figures (especially Figure 1) as it is currently hard to follow.

3\) Figure 2F. Please indicate what AR score was used and what is the y axis? Ideally the distribution for *GREB1* expression across the full data set should be shown and the ARsig-hi and ARsig-lo marked on this?

4\) Regarding Figure 4H, in the Discussion the authors conclude \"we show that elevated levels of *GREB1* in CRPC tumors correlate with a poor clinical response to enzalutamide, analogous to the prognostic impact of AR gene amplification\". This is inaccurate. The authors show increased expression in tumors collected at progression vs. baseline. Have these been controlled for tumor fraction and other potential biases?

5\) There are a few grammatical errors in the figure legends, such as in that of Figure 4H. Please correct.

10.7554/eLife.41913.036

Author response

> Essential revisions:
>
> 1\) Statistical tests/results should be added to the figure panels and should be more clearly specified throughout the text and in the figures.

Thank you for noting this. We have added statistical results in revised Figure 1D, 1H, 1I, Figure 1---figure supplement 1B, 1E, Figure 1---figure supplement 3B, Figure 2E, Figure 2---figure supplement 1A, Figure 3A, 3B, 3E, 3F, 3G, 3H, Figure 3---figure supplement 1A, 1B, Figure 3---figure supplement 2A, 2C, Figure 3---figure supplement 3A, 3B, 3D, 3E, Figure 4A, 4C, Figure 4---figure supplement 1A and 1E. We have also edited the figure legends to specify the statistical analysis used in each figure.

> 2\) The authors use both LNCAP and LNCaP with stably over-expressing AR (for xenograft work and based on previous studies). The use of these models needs to be clarified in the figures (especially Figure 1) as it is currently hard to follow.

We appreciate the feedback and have specified the cell lines throughout in the figures and figure legends.

> 3\) Figure 2F. Please indicate what AR score was used and what is the y axis? Ideally the distribution for GREB1 expression across the full data set should be shown and the ARsig-hi and ARsig-lo marked on this?

We used the same AR score as in the TCGA study (Cancer Genome Atlas Research, 2015; Hieronymus et al., 2006). The original Figure 2F did not have y-axis. As suggested by the reviewers, we've combined the original Figure 2F and 2G and now show the distribution of *GREB1, GHRHR* and *KLF8* expression across the 333 TCGA tumors. We have marked ARsig-lo and ARsig-hi cases to show that the expression of *GREB1*, but not *GHRHR* or *KLF8*, is increased in ARsig-hi cases (new Figure 2F). We have also analyzed the Pearson's correlation (*r*) between RNA level of each gene and AR score across the TCGA tumors and observed that only *GREB1* expression shows significantly positive correlation with AR score (*r*=0.55, P\<0.0001).

> 4\) Regarding Figure 4H, in the Discussion the authors conclude \"we show that elevated levels of GREB1 in CRPC tumors correlate with a poor clinical response to enzalutamide, analogous to the prognostic impact of AR gene amplification\". This is inaccurate. The authors show increased expression in tumors collected at progression vs baseline. Have these been controlled for tumor fraction and other potential biases?

We thank the reviewers for pointing this out and have edited the Discussion to clarify this. We did not intend to claim that *GREB1* is a prognostic biomarker (although future work may address this possibility).

Regarding tumor purity, we have analyzed tumor content and stromal signature scores of patient samples as described previously (Carter et al., 2012; Shah et al., 2017; Yoshihara et al., 2013). We observed no significant change in both tumor purity content and stromal signature score between pre- vs. post-enzalutamide setting, suggesting that increased *GREB1* expression is not caused by different tumor content between samples. These analyses are presented in new Figure 4---figure supplement 1F.

> 5\) There are a few grammatical errors in the figure legends, such as in that of Figure 4H. Please correct.

We appreciate the feedback and have corrected grammatical errors in figure legends.
